Preprint Article Version 1 This version is not peer-reviewed

Fractional Exhaled Nitric Oxide (FeNO) in Biomass Smoke-associated Chronic Obstructive Pulmonary Disease

Version 1 : Received: 27 August 2024 / Approved: 28 August 2024 / Online: 28 August 2024 (10:53:57 CEST)

How to cite: Silva-Gallardo, J.; Sansores, R. H.; Ramírez-Venegas, A.; Robles-Hernández, R.; Centeno-Saenz, G. I.; Hernández-Zenteno, R. J. Fractional Exhaled Nitric Oxide (FeNO) in Biomass Smoke-associated Chronic Obstructive Pulmonary Disease. Preprints 2024, 2024082011. https://doi.org/10.20944/preprints202408.2011.v1 Silva-Gallardo, J.; Sansores, R. H.; Ramírez-Venegas, A.; Robles-Hernández, R.; Centeno-Saenz, G. I.; Hernández-Zenteno, R. J. Fractional Exhaled Nitric Oxide (FeNO) in Biomass Smoke-associated Chronic Obstructive Pulmonary Disease. Preprints 2024, 2024082011. https://doi.org/10.20944/preprints202408.2011.v1

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a disease characterized by local and systemic inflammation independently of the risk factor; during the exacerbations, such inflammation is accentuated and amplified. A practical inflammatory marker and one with an applicable predictive value in the follow-up has been sought. FeNO has shown an excellent performance in that respect within the context of asthma and has also been studied in tobacco-smoke COPD (COPD-TS). In Biomass-smoke COPD (COPD-BS), this, to our knowledge, has not been evaluated. Objective: To measure FeNO levels in patients with COPD-BS and to compare these with those of patients with stable COPD-TS and in healthy controls. Methods: Transversal, observational, descriptive, comparative, and analytical study. A total of 57 patients, including 23 with COPD-BS, 17 with COPD-TS, and 17 healthy control subjects. The measurement of FeNO was carried out on all of these by means of the on-line chemiluminescence technique; the values were expressed in parts per billion (ppb) for their analysis. Results: It was observed that the FeNO values were similar between COPD-BS and COPD-TS and were significantly different between the healthy and stable COPD (both groups). No correlation was found between pulmonary function and symptoms with FeNO in any of the groups. Conclusions: The level of FeNO in stable COPD is found to be increased in a similar manner in COPD-BS and COPD-TS, with a significant difference on comparing it with that of the healthy subjects.

Keywords

Biomass COPD; FeNO; Inflammation

Subject

Medicine and Pharmacology, Pulmonary and Respiratory Medicine

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.